Pfizer Shuffle: Simmons Out, Brandicourt In At Emerging Markets And Established Products Unit
This article was originally published in The Pink Sheet Daily
David Simmons, head of established products and emerging markets at Pfizer, has jumped ship to lead global CRO PPD Inc. Olivier Brandicourt, currently head of primary care at the big pharma, will take Simmons’ place.
You may also be interested in...
The broadly experienced pharmaceutical executive – who has specialized particularly in emerging markets and infectious diseases – inherits a healthcare division that is in the midst of several product launches and has few near-term patent expirees.
New top leadership at PPD and Promedior; Pfizer names new presidents at two business units; Former FDA Commissioner von Eschenbach and former HHS Secretary Thompson take on board of director roles. More personnel announcements in this month’s column.
Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.